Key Highlights

• Continued dominance of global pharmaceutical sponsors
• Oncology remains the leading therapeutic area
• Strong concentration in Phase II–III studies
• Increased activity in metabolic and rare disease programs
• Growing number of innovative mechanism-of-action therapies

The May 2026 approval data continues to demonstrate Korea’s importance within global clinical development strategies. Multinational pharmaceutical companies and global biotechnology sponsors accounted for the majority of approvals, reinforcing Korea’s position as a preferred execution country for multinational clinical trials and registration-focused development programs.

From a therapeutic area perspective, oncology remained the dominant segment. Multiple studies were approved across pancreatic cancer, hepatocellular carcinoma, colorectal cancer, ovarian cancer, AML, and non-small cell lung cancer. This reflects the continued confidence of sponsors in Korea’s oncology infrastructure, experienced investigators, and ability to support complex patient recruitment requirements. At the same time, increasing competition for patient access suggests that strategic site selection is becoming even more critical.

Phase distribution continues to be concentrated in Phase II and Phase III studies. This trend indicates that Korea remains particularly attractive for proof-of-concept, pivotal, and confirmatory clinical programs where both recruitment efficiency and data quality are key success factors. Global sponsors continue to prioritize Korea for studies supporting future regulatory submissions.

Beyond oncology, several approvals were observed in metabolic diseases, autoimmune disorders, pulmonary diseases, ophthalmology, and rare diseases. The growing diversity of therapeutic areas suggests that Korea is expanding beyond traditional strengths and becoming increasingly important across a broader range of clinical development programs.

Another notable trend is the increasing presence of innovative modalities and next-generation therapeutics, including CDK2 degraders, antibody-drug conjugates (ADCs), T-cell redirecting therapies, and novel metabolic disease treatments. This indicates that Korea is not only serving as an execution market for late-stage development but is also becoming an important location for early clinical validation of emerging technologies.